|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Keith E. Murphy||Exec. Chairman||496,77k||N/D||1972|
|Dr. Jeffrey N. Miner||Chief Scientific Officer||303,75k||N/D||1962|
|Mr. Thomas Einar Jurgensen J.D., MS||Gen. Counsel & Corp. Sec.||548,03k||N/D||1957|
|Ms. Vaidehi Joshi||Director of Discovery Biology & Director||4,42k||N/D||1986|
|Mr. Thomas P. Hess CPA, MBA||Pres & CFO||N/D||N/D||1964|
|Dr. Curtis M. Tyree Ph.D.||Sr. VP of Strategy & Bus. Devel.||N/D||N/D||N/D|
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
L'ISS Governance QualityScore di Organovo Holdings, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.